Pneumocystis carinii Pneumonia During Maintenance Anti–Tumor Necrosis Factor-α Therapy with Infliximab for Crohn’s Disease
Open Access
- 1 September 2004
- journal article
- research article
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 10 (5) , 657-660
- https://doi.org/10.1097/00054725-200409000-00025
Abstract
Background. Clinical trials using infliximab have not reported cases of Pneumocystis carinii pneumonia (PCP), and PCP infection during standard medical treatmenKeywords
This publication has 40 references indexed in Scilit:
- Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm CountyGut, 2004
- Azathioprine and anti-TNFα therapies in Crohn’s disease: a review of pharmacology, clinical efficacy and safetyPharmacological Research, 2003
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialPublished by Elsevier ,2002
- Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing AgentNew England Journal of Medicine, 2001
- Pneumocystis cariniipneumonia in patients receiving immunosuppressive drugs for dermatological diseasesBritish Journal of Dermatology, 1999
- Infliximab for the Treatment of Fistulas in Patients with Crohn's DiseaseNew England Journal of Medicine, 1999
- Pneumocystis Carinii pneumonia postrestorative proctocolectomy for ulcerative colitis: A role for perioperative prophylaxis in the cyclosporine era?Diseases of the Colon & Rectum, 1997
- Cyclosporine Treatment of Inflammatory Bowel DiseaseMayo Clinic Proceedings, 1992
- Alveolar macrophages in AIDS patients: increased spontaneous tumour necrosis factor-alpha production inPneumocystis cariniipneumoniaClinical and Experimental Immunology, 1990
- Atypical Pneumocystis carinii PneumoniaSouthern Medical Journal, 1983